FierceBiotech 2026-02-12 Icon shares plummet after CRO reveals accounting investigation, pulls 2025 guidance
FierceBiotech 2026-02-12 Lundbeck’s migraine prevention treatment sees ph. 2 success after trial’s earlier setback
FierceBiotech 2026-02-12 BridgeBio preps approval push after dwarfism drug increases children's height in phase 3
FierceBiotech 2026-02-12 Langer-backed biotech looks to end cancer recurrence with surgical revolution
FierceBiotech 2026-02-12 Agilent companion diagnostic lands FDA nod alongside Keytruda's latest cancer approval
FierceBiotech 2026-02-12 Seres to lay off 30% of employees, pause lead program in latest strategic shift
FierceBiotech 2026-02-12 Sanofi ousts Paul Hudson after ‘bumpy ride’, poaches Merck KGaA CEO to lead the French pharma
FierceBiotech 2026-02-12 UPDATE: After Moderna's rebuke, HHS stands behind FDA decision to spurn mRNA flu filing
FierceBiotech 2026-02-11 ‘The only thing that saves us is data’: Allogeneic CAR-T biotechs fight for relevance as industry moves on
FierceBiotech 2026-02-11 Upstream posts Tezspire-like asthma efficacy in phase 2 but falls short of best-case scenario
FierceBiotech 2026-02-11 Madrigal pens $4.4B deal for Ribo's preclinical siRNA programs in latest Rezdiffra MASH play
FierceBiotech 2026-02-11 GE HealthCare debuts tech to help hospitals remotely maintain bedside ECG stations
FierceBiotech 2026-02-11 Moderna hit with FDA refusal-to-file letter for mRNA flu shot, issues sharp rebuke of agency's rationale
FierceBiotech 2026-02-10 Kailera, Hengrui tout up to 12% weight loss in midstage study for obesity pill
FierceBiotech 2026-02-10 Merck teams up with British medtech to boost vaginal therapeutics delivery system
FierceBiotech 2026-02-10 AstraZeneca reveals oral GLP-1 scored phase 2 wins but holds back weight loss data
FierceBiotech 2026-02-10 Nektar eczema candidate 'checked all of the boxes' in long-term phase 2 data